Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

BACKGROUND: Nivolumab has shown improved survival in the treatment of advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy. We assessed the safety and activity of combination nivolumab plus ipilimumab as first-line therapy for NSCLC. METHODS: The open-label, phase 1, mult...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Lancet Oncol
Auteurs principaux: Hellmann, Matthew D, Rizvi, Naiyer A, Goldman, Jonathan W, Gettinger, Scott N, Borghaei, Hossein, Brahmer, Julie R, Ready, Neal E, Gerber, David E, Chow, Laura Q, Juergens, Rosalyn A, Shepherd, Frances A, Laurie, Scott A, Geese, William J, Agrawal, Shruti, Young, Tina C, Li, Xuemei, Antonia, Scott J
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5476941/
https://ncbi.nlm.nih.gov/pubmed/27932067
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30624-6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires